Glycine N-methyltransferase is a favorable prognostic marker for human cholangiocarcinoma

Yu Chuen Huang, Marcelo Chen, Yi Ming Shyr, Cheng Hsi Su, Chi Kuan Chen, Anna Fen Yau Li, Donald Ming Tak Ho, Yi Ming Arthur Chen

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background and Aim: Glycine N-methyltransferase (GNMT) is a susceptibility gene for human hepatocellular carcinoma (HCC). We previously reported that GNMT expression is diminished in HCC. Here we report our examination of GNMT expression patterns in cholangiocarcinoma and the relationship between its expression and prognosis. Methods: We analyzed GNMT expression in tumor tissues from 33 cholangiocarcinoma patients (19 male) using immunohistochemistry (IHC) procedures with a GNMT monoclonal antibody (mAb 4-17). GNMT expression intensity and percentages were scored on a scale of 0 to 6. The association between GNMT expression and survival was analyzed using the Kaplan-Meier method, and prognostic factors were evaluated with a multivariate Cox proportional hazards regression model. Results: High GNMT expression was found in epithelial cells of normal bile ducts. Six of 33 (18.2%) cholangiocarcinoma tissues had no GNMT expression. A statistically significant difference was noted in GNMT expression between male and female patients (68.4% vs 100%, P < 0.05). Compared to patients with GNMT expression scores > 3, the death hazard ratio for patients with GNMT scores ≤ 3 was 3.68 (95% confidence interval = 1.17-11.59, P < 0.05). Conclusions: GNMT expression is a favorable prognosis predictor for cholangiocarcinoma.

Original languageEnglish
Pages (from-to)1384-1389
Number of pages6
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume23
Issue number9
DOIs
Publication statusPublished - Jan 1 2008
Externally publishedYes

Fingerprint

Glycine N-Methyltransferase
Cholangiocarcinoma
Hepatocellular Carcinoma

Keywords

  • Cholangiocarcinoma
  • Glycine N-methyltransferase
  • Hepatocellular carcinoma
  • Immunohistochemistry

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Glycine N-methyltransferase is a favorable prognostic marker for human cholangiocarcinoma. / Huang, Yu Chuen; Chen, Marcelo; Shyr, Yi Ming; Su, Cheng Hsi; Chen, Chi Kuan; Li, Anna Fen Yau; Ho, Donald Ming Tak; Chen, Yi Ming Arthur.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 23, No. 9, 01.01.2008, p. 1384-1389.

Research output: Contribution to journalArticle

Huang, Yu Chuen ; Chen, Marcelo ; Shyr, Yi Ming ; Su, Cheng Hsi ; Chen, Chi Kuan ; Li, Anna Fen Yau ; Ho, Donald Ming Tak ; Chen, Yi Ming Arthur. / Glycine N-methyltransferase is a favorable prognostic marker for human cholangiocarcinoma. In: Journal of Gastroenterology and Hepatology (Australia). 2008 ; Vol. 23, No. 9. pp. 1384-1389.
@article{684d7dea56974cb4a8d27eef3927c633,
title = "Glycine N-methyltransferase is a favorable prognostic marker for human cholangiocarcinoma",
abstract = "Background and Aim: Glycine N-methyltransferase (GNMT) is a susceptibility gene for human hepatocellular carcinoma (HCC). We previously reported that GNMT expression is diminished in HCC. Here we report our examination of GNMT expression patterns in cholangiocarcinoma and the relationship between its expression and prognosis. Methods: We analyzed GNMT expression in tumor tissues from 33 cholangiocarcinoma patients (19 male) using immunohistochemistry (IHC) procedures with a GNMT monoclonal antibody (mAb 4-17). GNMT expression intensity and percentages were scored on a scale of 0 to 6. The association between GNMT expression and survival was analyzed using the Kaplan-Meier method, and prognostic factors were evaluated with a multivariate Cox proportional hazards regression model. Results: High GNMT expression was found in epithelial cells of normal bile ducts. Six of 33 (18.2{\%}) cholangiocarcinoma tissues had no GNMT expression. A statistically significant difference was noted in GNMT expression between male and female patients (68.4{\%} vs 100{\%}, P < 0.05). Compared to patients with GNMT expression scores > 3, the death hazard ratio for patients with GNMT scores ≤ 3 was 3.68 (95{\%} confidence interval = 1.17-11.59, P < 0.05). Conclusions: GNMT expression is a favorable prognosis predictor for cholangiocarcinoma.",
keywords = "Cholangiocarcinoma, Glycine N-methyltransferase, Hepatocellular carcinoma, Immunohistochemistry",
author = "Huang, {Yu Chuen} and Marcelo Chen and Shyr, {Yi Ming} and Su, {Cheng Hsi} and Chen, {Chi Kuan} and Li, {Anna Fen Yau} and Ho, {Donald Ming Tak} and Chen, {Yi Ming Arthur}",
year = "2008",
month = "1",
day = "1",
doi = "10.1111/j.1440-1746.2008.05488.x",
language = "English",
volume = "23",
pages = "1384--1389",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Glycine N-methyltransferase is a favorable prognostic marker for human cholangiocarcinoma

AU - Huang, Yu Chuen

AU - Chen, Marcelo

AU - Shyr, Yi Ming

AU - Su, Cheng Hsi

AU - Chen, Chi Kuan

AU - Li, Anna Fen Yau

AU - Ho, Donald Ming Tak

AU - Chen, Yi Ming Arthur

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Background and Aim: Glycine N-methyltransferase (GNMT) is a susceptibility gene for human hepatocellular carcinoma (HCC). We previously reported that GNMT expression is diminished in HCC. Here we report our examination of GNMT expression patterns in cholangiocarcinoma and the relationship between its expression and prognosis. Methods: We analyzed GNMT expression in tumor tissues from 33 cholangiocarcinoma patients (19 male) using immunohistochemistry (IHC) procedures with a GNMT monoclonal antibody (mAb 4-17). GNMT expression intensity and percentages were scored on a scale of 0 to 6. The association between GNMT expression and survival was analyzed using the Kaplan-Meier method, and prognostic factors were evaluated with a multivariate Cox proportional hazards regression model. Results: High GNMT expression was found in epithelial cells of normal bile ducts. Six of 33 (18.2%) cholangiocarcinoma tissues had no GNMT expression. A statistically significant difference was noted in GNMT expression between male and female patients (68.4% vs 100%, P < 0.05). Compared to patients with GNMT expression scores > 3, the death hazard ratio for patients with GNMT scores ≤ 3 was 3.68 (95% confidence interval = 1.17-11.59, P < 0.05). Conclusions: GNMT expression is a favorable prognosis predictor for cholangiocarcinoma.

AB - Background and Aim: Glycine N-methyltransferase (GNMT) is a susceptibility gene for human hepatocellular carcinoma (HCC). We previously reported that GNMT expression is diminished in HCC. Here we report our examination of GNMT expression patterns in cholangiocarcinoma and the relationship between its expression and prognosis. Methods: We analyzed GNMT expression in tumor tissues from 33 cholangiocarcinoma patients (19 male) using immunohistochemistry (IHC) procedures with a GNMT monoclonal antibody (mAb 4-17). GNMT expression intensity and percentages were scored on a scale of 0 to 6. The association between GNMT expression and survival was analyzed using the Kaplan-Meier method, and prognostic factors were evaluated with a multivariate Cox proportional hazards regression model. Results: High GNMT expression was found in epithelial cells of normal bile ducts. Six of 33 (18.2%) cholangiocarcinoma tissues had no GNMT expression. A statistically significant difference was noted in GNMT expression between male and female patients (68.4% vs 100%, P < 0.05). Compared to patients with GNMT expression scores > 3, the death hazard ratio for patients with GNMT scores ≤ 3 was 3.68 (95% confidence interval = 1.17-11.59, P < 0.05). Conclusions: GNMT expression is a favorable prognosis predictor for cholangiocarcinoma.

KW - Cholangiocarcinoma

KW - Glycine N-methyltransferase

KW - Hepatocellular carcinoma

KW - Immunohistochemistry

UR - http://www.scopus.com/inward/record.url?scp=49849084374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49849084374&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1746.2008.05488.x

DO - 10.1111/j.1440-1746.2008.05488.x

M3 - Article

AN - SCOPUS:49849084374

VL - 23

SP - 1384

EP - 1389

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 9

ER -